Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology

Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology

Hypertrophic cardiomyopathy (HCM) is a heterogeneous group of heart muscle disorders that affects millions, with an incidence from 1 in 500 to 1 in 200. Factors such as genetics, age, gender, comorbidities, and environmental factors may contribute to the course of this disease. Diagnosis of HCM has...

Full description

Saved in:
Bibliographic Details
Main Authors: Ewelina Młynarska, Ewa Radzioch, Bartłomiej Dąbek, Klaudia Leszto, Alicja Witkowska, Witold Czarnik, Weronika Jędraszak, Jacek Rysz, Beata Franczyk
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Biomedicines
Subjects:
cardiomyopathies
hypertrophic cardiomyopathy
mavacamten
cardiac therapeutics
Online Access:https://www.mdpi.com/2227-9059/12/12/2675
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2227-9059/12/12/2675

Similar Items